[Anti-inflammatory effect of peroxisome proliferator-activated receptor-gamma incultured human mesangial cells].
To investigate whether peroxisome proliferator-activator receptor-gamma (PPARgamma) could retard the inflammatory challenge from human mesangial cells. Based on the inflammatory mesangial cell model followed by IL-1beta, the levels of IL-6 and TNF-gamma in the supernatants were measured by enzyme-linked immunosorbant assay (ELISA). PPARgamma protein expression of human mesangial cell lines (HMCL) lysate was detected with Western blot. PPARgamma, IL-6 and TNF-gamma mRNA expression in HMCL lysate were measured by semi-quantitative RT-PCR assay. The levels of IL-6 and TNF-gamma in HMCL supernatants were dramatically increased when cultured HMCL were stimulated by IL-1beta (10 ng/ml). Protein and mRNA expressions of PPARgamma in IL-1beta challenge cells were significantly increased than observed in untreated cells. However, PPARgamma agonist troglitazone down-regulated mRNA and protein expression of PPARgamma from IL-1beta challenge HMCLs. PPARgamma agonists troglitazone, rosiglitazone, and 15-deoxy-Delta(12, 14)-prosglandin J(2) significantly decreased the upexpression of TNF-alpha and IL-6 in HMCL supernatants stimulated by IL-1beta. Furthermore, troglitazone down-regulated TNF-alpha and IL-6 mRNA expression levels of HMCLs. These data suggest that PPARgamma play an important role in response to inflammatory stress in mesangial cells. PPARgamma may prove to be a pharmacological target in glomerulonephritis.